https://doi.org/10.55788/8f0ebfc8
Globally, almost 43% of asthma patients are non-adherent to their inhalation therapy [1]. Digital/smart inhalers provide objective data on adherence and have been shown to improve medication adherence in the short term [2,3]. âWe donât know much about the long-term adherence,â Susanne J van de Hei (University Medal Center Groningen, the Netherlands) explained [4]. To evaluate the effect of a digital inhaler programme (Turbu+ InsightsTM) on medication adherence in uncontrolled asthma patients, it was compared with a control group over a 12-month period. Adult asthma patients were recruited via general practices, pharmacies, and via social media. All participants had an Asthma Control Questionnaire (ACQ)-5 score â„0.57 and used an inhaler (SymbicortÂź TurbuhalerÂź) â„8 weeks. They were randomised to either a control or an intervention group. Participants were able to view medication use and set reminders in the digital inhaler programme. Efficacy parameters were medication adherence (primary endpoint), measured by the digital programme, and asthma control, as measured by ACQ-5, where a change of â€-0.5 in the ACQ-5 score was seen as a minimally important difference.
âShort-term, the adherence was much better in the intervention group, but after a while, it got worse,â Ms van de Hei said. At week 2, there was indeed a significantly higher adherence in the intervention arm (odds ratio (OR) 2.19; 95% CI 1.63â2.95). However, the difference between groups declined over time, and there was no significant difference between the groups at the end of the study. In contrast, asthma control significantly improved in the digital inhaler programme users over time, compared with the control arm (P=0.006). In addition, those using the digital inhaler program were 3 times more likely to reach a minimally important difference in the ACQ-5.
- Hassan M, et al. J Asthma 2020;57(12):1379â88.
- Chan AH, et al. Lancet Respir Med 2015;3:210-9
- Mac Hale E, et al. Lancet Respir Med 2023;11:591-601.
- Van de Hei S. Effects of a digital inhaler on medication adherence and clinical outcomes in primary care asthma patients: a cluster RCT. Abstract 3211, ERS International Congress 2023, 9â13 September, Milan, Italy.
- Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Know Your Lemons for breast cancer detection Next Article
Tezepelumab therapy: hints toward a disease-modifying effect? »
« Know Your Lemons for breast cancer detection Next Article
Tezepelumab therapy: hints toward a disease-modifying effect? »
Table of Contents: ERS 2023
Featured articles
Letter from the Editor
Best of the Posters
sRAGE: A novel potential biomarker to assess the risk of acute respiratory events
Most severe asthma patients are candidates for biologic therapy on a global scale
Aspergillus infections: resistance to azole treatment increased in the presence of diesel particles
Asthma in 2023
Tapering from high-dose inhaled corticosteroids possible in most asthma patients treated with benralizumab
Tezepelumab therapy: hints toward a disease-modifying effect?
Digital inhaler programme improves asthma control also in the long term, but not long-term adherence
Respiratory health in children
Large infant study demonstrates the importance of a mature microbiome
Healthy maternal lifestyle during pregnancy reduces wheezing and rhinitis in infants
Mechanism of autophagy in a newborn responsible for deleterious effect of air pollutants
COPD: New Developments
Gabapentinoids increase risk of exacerbations in COPD
Future treatment of fatigue in COPD: 4 possible targets identified
Pulmonary Consequences of Long COVID
Women at higher risk of functional respiratory complaints following a COVID-19 infection
Elevated myeloid inflammation and complement activation present in various phenotypes of long COVID
Pulmonary Arterial Hypertension (PAH): Novel Developments
Encouraging long-term outcomes observed in the treatment of PAH with sotatercept
Chronic thromboembolic pulmonary hypertension: surgery entails encouraging long-term results
Women with pulmonary hypertension have better survival chances than men
Rare Diseases in 2023
Primary ciliary dyskinesia: Idrevloride shows promising results in phase 2 trial
Promising new agent as treatment for pulmonary fibrosis
Novel immunomodulator offers hope to reduce steroid dependency in sarcoidosis
Other Research of Interest
Tacrolimus versus cyclosporin: Less lung graft dysfunction
CPAP effective in reducing cardiovascular mortality in a practice study
Gefapixant curbs chronic cough independent of its duration
Related Articles
June 10, 2024
Novel RSV vaccine to prevent serious respiratory illness
October 29, 2020
Longer hospital stay and fewer transplants for frail ILD patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com